Post by Deleted on Jul 29, 2018 13:43:32 GMT
This tweet (along with many similar) from FDA head Gottlieb could really help push along the entire COCP pipeline if more broadly implemented as Gottlieb would like. It’s Hardly a new concept but individual FDA divisions are often resistant to it.
“Surrogate endpoints are another clinical trial modernization tool. These endpoints are often used when clinical outcomes take a long time to study or when the surrogate’s ability to predict clinical benefit, such as reducing the HIV viral load, is well known.”
“Surrogate endpoints are another clinical trial modernization tool. These endpoints are often used when clinical outcomes take a long time to study or when the surrogate’s ability to predict clinical benefit, such as reducing the HIV viral load, is well known.”
